CLOV · Clover Health Investments, Corp. /De - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $749.19M | - | $496.65M | $477.62M | $462.33M | - | $330.99M | $356.26M | $346.92M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | $81.21M | $107.91M | $81.76M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $74.63M | - | $48.95M | $48.48M | $50.67M | - | $35.20M | $44.42M | $44.57M | - |
| Total Operating Expenses | $721.86M | - | $521.03M | $488.18M | $463.61M | - | $339.77M | $349.07M | $369.63M | - |
| D&A | $515.0K | - | $406.0K | $394.0K | $466.0K | - | $339.0K | $330.0K | $318.0K | - |
| Operating Income | $27.33M | - | ($24.38M) | ($10.56M) | ($1.27M) | - | ($8.79M) | $7.19M | ($22.70M) | - |
| Interest Expense | - | - | - | - | - | - | $0 | $0 | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | $27.33M | - | ($24.38M) | ($10.58M) | ($1.27M) | - | ($9.15M) | $7.41M | ($19.17M) | - |
| EPS - Basic | $0.05 | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | $0.05 | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $173.26M | $78.30M | $190.06M | $188.65M | $155.44M | $194.54M | $287.96M | $254.77M | $208.25M | $122.86M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $448.02M | $307.86M | $330.92M | $362.94M | $331.41M | $343.12M | $432.73M | $549.58M | $552.74M | $427.97M |
| Total Assets | $697.73M | $541.01M | $559.66M | $574.99M | $583.72M | $580.74M | $653.01M | $674.21M | $671.77M | $570.67M |
| Current Liabilities | $336.58M | $208.82M | $193.45M | $201.95M | $215.65M | $213.52M | $279.63M | $324.51M | $356.39M | $261.12M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $358.30M | $232.31M | $218.73M | $230.81M | $247.64M | $239.60M | $310.85M | $349.32M | $379.30M | $284.28M |
| Stockholders' Equity | $341.14M | $308.70M | $340.93M | $344.18M | $336.07M | $341.14M | $342.17M | $324.89M | $292.47M | $286.39M |
| Retained Earnings | ($2.26B) | ($2.29B) | ($2.24B) | ($2.21B) | ($2.20B) | ($2.20B) | ($2.18B) | ($2.17B) | ($2.18B) | ($2.16B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $107.89M | - | - | - | ($16.29M) | - | - | - | $25.93M | - |
| Investing Cash Flow | ($5.07M) | - | - | - | $8.93M | - | - | - | $9.19M | - |
| Financing Cash Flow | ($7.86M) | - | - | - | ($31.74M) | - | - | - | ($3.36M) | - |
| CapEx | $854.0K | - | - | - | $185.0K | - | - | - | $445.0K | - |
| Free Cash Flow | $107.04M | - | - | - | ($16.48M) | - | - | - | $25.49M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 24.5% | 30.3% | 23.6% | - |
| Operating margin | 3.6% | - | -4.9% | -2.2% | -0.3% | - | -2.7% | 2.0% | -6.5% | - |
| EBITDA margin | 3.7% | - | -4.8% | -2.1% | -0.2% | - | -2.6% | 2.1% | -6.5% | - |
| Net margin | 3.6% | - | -4.9% | -2.2% | -0.3% | - | -2.8% | 2.1% | -5.5% | - |
| Free cash flow margin | 14.3% | - | - | - | -3.6% | - | - | - | 7.3% | - |
| FCF / Net income | 3.92 | - | - | - | 12.93 | - | - | - | -1.33 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 10.0% | - | 9.9% | 10.2% | 11.0% | - | 10.6% | 12.5% | 12.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | 3.9% | - | -4.4% | -1.8% | -0.2% | - | -1.4% | 1.1% | -2.9% | - |
| Return on equity | 8.0% | - | -7.2% | -3.1% | -0.4% | - | -2.7% | 2.3% | -6.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.33 | 1.47 | 1.71 | 1.80 | 1.54 | 1.61 | 1.55 | 1.69 | 1.55 | 1.64 |
| Quick ratio | 1.33 | 1.47 | 1.71 | 1.80 | 1.54 | 1.61 | 1.55 | 1.69 | 1.55 | 1.64 |
| Cash ratio | 0.51 | 0.37 | 0.98 | 0.93 | 0.72 | 0.91 | 1.03 | 0.79 | 0.58 | 0.47 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.05 | 1.75 | 1.64 | 1.67 | 1.74 | 1.70 | 1.91 | 2.08 | 2.30 | 1.99 |
| Liabilities / Assets | 0.51 | 0.43 | 0.39 | 0.40 | 0.42 | 0.41 | 0.48 | 0.52 | 0.56 | 0.50 |
| Efficiency | ||||||||||
| Asset turnover | 1.07 | - | 0.89 | 0.83 | 0.79 | - | 0.51 | 0.53 | 0.52 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 35.2x | - | - | - | - | - | - | - | - | - |
| P / B | 2.7x | - | 4.6x | 4.1x | 5.3x | - | 4.0x | 1.9x | 1.3x | - |
| P / S | 1.3x | - | 3.2x | 3.0x | 3.9x | - | 4.2x | 1.7x | 1.1x | - |
| EV / EBITDA | 27.4x | - | - | - | - | - | - | 47.1x | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 62.0% | - | 50.1% | 34.1% | 33.3% | - | -31.3% | -30.6% | -34.3% | - |
| Revenue CAGR (3y) | 12.4% | - | -16.6% | -17.4% | -19.1% | - | 25.1% | -4.8% | 28.0% | - |
| Revenue CAGR (5y) | 35.3% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | 28.7% | 40.7% | 47.9% | - |
| Operating income growth (YoY) | - | - | -177.5% | - | 94.4% | - | 78.8% | - | 68.7% | - |
| Net income growth (YoY) | - | - | -166.3% | - | 93.4% | - | 77.9% | - | 73.6% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | -67.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 1.5% | -9.5% | -0.4% | 5.9% | 14.9% | 19.1% | 6.3% | -1.7% | -9.5% | -17.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$49.81M totalInsurance Segment$49.81M · 100.0%
Peer comparison
Same SIC group: Hospital & Medical Service Plans
Comparing CLOVER HEALTH INVESTMENTS against the 5 most active filers in the same SIC group.